ANL
$7.40+0.04 (+0.54%)
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatm...
Recent News
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why
Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed Chair
US stocks look set to open lower in Friday's trading session as investors seem calmed by President D
Investors Calmed by Trump's Choice of Warsh as Fed Chair, Look Ahead to Inflation Data
US stock futures are tracking lower in Friday's premarket session, but rebounding from earlier level
Individual investors are Adlai Nortye Ltd.'s (NASDAQ:ANL) biggest owners and were rewarded after market cap rose by US$65m last week
Key Insights Adlai Nortye's significant individual investors ownership suggests that the key decisions are influenced...